MaaT013 as Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients
Status:
Not yet recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
MaaT013 showed interesting results in steroids and ruxolitinib-resistant aGVHD patients with
gut involvement (55% ORR at D28) and 47% and 39% OS at 6 and 12 months respectively (Malard
2020), therefore warrant being tested as salvage therapy in steroid and JAK
inhibitors-resistant GI-aGvHD patients. Given the absence of an approved 3rd line strategy or
2nd line strategy in ruxolitinib intolerant patients and the extremely poor prognosis of
these patients, who are mostly left with no viable therapeutic option, a single-arm
open-label design was proposed.